OncoHost Launches NSCLC Test in the U.S.
OncoHost, a diagnostics company centered on predictive biomarker development patient care, launched its non-small lung cancer (NSCLC) test.
Category: Lung Cancer
Lung Cancer
Latest
Lung Cancer
Latest
EarlySign Signs Agreement with Roche on AI Solution for Early Lung Cancer Detection
Medial EarlySign signed a new partnership with Roche to create innovative, evidence-based solutions for early detection of lung cancer.
Lung Cancer
Latest
Blood Drops May Help Detect Early-Stage Lung Cancer
A study shows proof-of-concept of using a drop of blood to reveal lung cancer, which may help diagnose early-stage lung cancer in asymptomatic patients.
Community Oncologists Use Biomarker Testing Less Than Academic Clinicians
A recent report showed less than half of community oncologists used biomarker testing for lung cancer — compared to 73% of academic clinicians.
Read More
AI Blood Test Can ID Lung Cancers with High Accuracy
Researchers have developed novel artificial intelligence blood testing technology that detected over 90% of lung cancers from 800 samples.
Read More
New Liquid Biopsy for Lung Cancer Has High Detection Rate
Delfi Diagnostics’s lung cancer screening technology, which analyzes genome-wide cell-free DNA fragmentation profiles, detected 90% of cases.
Read More
Validation Study: Nasal Swab Test Can Significantly Improve Early Lung Cancer Detection
The new findings show the Percepta Nasal Swab, a first-of-its-kind genomic test, accurately classifies lung cancer risk in current or former smokers with lung nodules so that those with benign nodules may safely avoid unnecessary additional procedures.
Read More
Biodesix Announces Liquid Biopsy NGS Test with 72-Hour Turnaround
The study showed that the rapid liquid biopsy NGS test was able to accurately detect actionable genomic alterations in patients with NSCLC with a turnaround time of only 72 hours.
Read More
Oncocyte to Acquire Chronix Biomedical
The transaction includes proprietary IP and technology for blood-based immune therapy monitoring and for transplant rejection testing.
Read More
Spectrum Solutions, UCLA Collaborate on Saliva-Based NGS Liquid Biopsy Research for Early Detection of Lung Cancer
Study to focus on using saliva in the analysis of cell-free circulating tumor DNA to accurately and noninvasively detect non-small cell lung cancer.
Read More
BioAffinity Automated Flow Cytometry Test Detects Lung Cancer in Sputum
The test validation trial resulted in CyPath Lung specificity of 88% and sensitivity of 82%, similar to far more invasive procedures currently used to diagnose lung cancer.
Read More
FDA Approves First CDx for Expanded EGFR TKI Therapies in NSCLC Patients
The group claim will also enable the test to be used as a CDx for any future approved EGFR TKI therapies targeting the same mutations.
Read More
FDA Approves New FoundationOne Liquid CDx Companion Diagnostic Indications for 3 Cancer Therapies
FDA approved FoundationOne Liquid CDx for three new companion diagnostic indications: Piqray in advanced or metastatic breast cancer; Rubraca in advanced ovarian cancer; and Alecensa in a certain type of metastatic non-small cell lung cancer.
Read More
Large Prospective Lung Cancer Study to Be Presented at ESMO
Idylla reduced EGFR mutation testing turnaround time by more than a week versus reference methods for patients with NSCLC.
Read More
FDA Approves First NGS-Based CDx for RET Fusion-Positive NSCLC
Thermo Fisher Scientific’s Oncomine Dx Target Test simultaneously evaluates 23 genes clinically associated with NSCLC.
Read More
Thermo Fisher, Hengrui Therapeutics to Develop CDx for NSCLC
The companion diagnostic will leverage the Oncomine Precision Assay to identify non-small cell lung cancer patients with HER2 mutations.
Read More
FDA Approves First Liquid Biopsy NGS Companion Diagnostic
This is the first approval to combine two technologies—NGS and liquid biopsy—in one diagnostic in order to guide treatment decisions.
Read More
Israel Expands Non-Small Cell Lung Cancer Testing Coverage
Israeli laboratories are approved to use molecular profiling assays for NSCLC patients using Thermo Fisher Scientific’s Oncomine Comprehensive Assay Plus.
Read More